Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Glioblastoma 2Spondylitis, Ankylosing 1Signs and Symptoms 1Psoriasis 1Nutrition Disorders 1Lymphoma 1Leukemia, Myeloid, Acute 1Insulin Resistance 1Inflammatory Bowel Diseases 1Glioma 1Gastroparesis 1Feeding and Eating Disorders 1Esophageal Neoplasms 1Epilepsy 1Dumping Syndrome 1Diarrhea 1Colorectal Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Tea 3Polyethylene Glycols 3Blood Specimen Collection 3Standard of Care 2Lidocaine 2Infliximab 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2Colonoscopy 2Biopsy 2Adalimumab 2sodium phosphate 1purine 1prucalopride 1polyethylene glycol 400 1picosulfate sodium 1fumaric acid 1Tumor Necrosis Factor Inhibitors 1Thrombin Time 1Surveys and Questionnaires 1Surgical Tape 1Sulfasalazine 1Spectrum Analysis, Raman 1Single-Balloon Enteroscopy 1Registries 1Proctocolectomy, Restorative 1Practice Guidelines as Topic 1Pneumococcal Vaccines 1Phlebotomy 1Passive Cutaneous Anaphylaxis 1Papillomavirus Vaccines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Inflammatory Bowel Diseases × Sulfasalazine × Clear all
NCT02376478 2015-03-03

On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection

Medical University of Vienna

Completed
222 enrolled

Psoriasis, Inflammatory Bowel Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡